Results 181 to 190 of about 19,613 (205)

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

International Journal of Toxicology
Aficamten (CK-3773274) is a cardiac myosin inhibitor in development for the treatment of hypertrophic cardiomyopathy (HCM), a commonly inherited heart condition often characterized as a disease of the sarcomere. Aficamten reduces pathologic cardiac hypercontractility by selectively binding to an allosteric site on cardiac myosin.
Michael K. Pugsley, Darren T. Hwee, Brett R. Winters, Jingying Wang, Eva R. Chin, Bradley P. Morgan, Fady I. Malik   +6 more
openaire   +2 more sources

Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy

Circulation, 2023
Aslan Teyfik Turer, Andrew Wang
openaire   +2 more sources

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential

Expert Opinion on Investigational Drugs, 2023
Shiavax J Rao, Beani Forst, Amreen K Kanwal, Arjun Kanwal, Wilbert S. Aronow, Srihari S Naidu   +5 more
openaire   +2 more sources

Cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy (literature review)

Pharmateca, 2023
L.V. Kononenko Kononenko, G.G. Taradin Taradin, G.A. Ignatenko Ignatenko   +2 more
openaire   +1 more source

Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin

Circulation, 2023
, Chisato Okamoto, Hidetaka Kioka
exaly  

Update on Cardiac Myosin Inhibitors and Potential Role in Treating Obstructive Hypertrophic Cardiomyopathy

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2023
Michael J, Litt, Sharlene M, Day
openaire   +2 more sources

Cryo-EM structure of the human cardiac myosin filament

Nature, 2023
Campbell Ks, Raúl Padron, Roger Craig   +2 more
exaly  

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: the need for precision medicine

European Heart Journal
openaire   +2 more sources

Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction

Circulation, 2017
Patrick Badertscher, Beata Morawiec, Christian Müller   +2 more
exaly  

Development of clinically viable non-muscle myosin II small molecule inhibitors

Cell
Courtney A Miller
exaly